Table 1.
Comparison of the percentage of germline DNA damage response mutations in prostate cancer.
| Gene | DDR Pathway | Percentage (%) of Germline Mutations in Tested Prostate Cancer Patients | |
|---|---|---|---|
| Nicolosi et al. [75] | Pritchard et al. [61] | ||
| ATM | Homologous Recombination | 2.03 | 1.59 |
| ATR | Homologous Recombination | Not tested | 0.29 |
| BRCA1 | Homologous Recombination | 1.25 | 0.87 |
| BRCA2 | 4.74 | 5.35 | |
| BARD1 | Homologous Recombination | 0.00 | 0.00 |
| BRIP1 | Homologous Recombination | 0.28 | 0.18 |
| CDKN2a | p16/cyclin-dependent kinase/retinoblastoma gene pathway | 0.13 | Not tested |
| CHEK2 | Homologous Recombination | 2.88 | 1.87 |
| FAM175A | Homologous Recombination | Not tested | 0.18 |
| GEN1 | Homologous Recombination | Not tested | 0.46 |
| MLH1 | Mismatch Repair | 0.06 | 0.00 |
| MSH2 | 0.69 | 0.14 | |
| MSH6 | 0.45 | 0.14 | |
| NBN | Homologous Recombination | 0.32 | 0.29 |
| PALB2 | Homologous Recombination | 0.56 | 0.43 |
| PMS2 | Mismatch Repair | 0.54 | 0.29 |
| RAD51C | Homologous Recombination | 0.21 | 0.14 |
| RAD51D | Homologous Recombination | 0.15 | 0.43 |